Insider Selling: Atara Biotherapeutics (NASDAQ:ATRA) Major Shareholder Sells $3,165,804.60 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) major shareholder Innovation Ltd Panacea sold 313,446 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $10.10, for a total value of $3,165,804.60. Following the transaction, the insider directly owned 1,011,000 shares of the company’s stock, valued at $10,211,100. This trade represents a 23.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Atara Biotherapeutics Stock Performance

Shares of NASDAQ ATRA opened at $10.48 on Thursday. The stock has a 50 day moving average price of $5.59 and a 200 day moving average price of $9.15. Atara Biotherapeutics, Inc. has a 52 week low of $3.92 and a 52 week high of $19.15. The stock has a market capitalization of $89.18 million, a PE ratio of -15.64 and a beta of -0.30.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.04. Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 40.91%.The firm had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $2.90 million. As a group, research analysts forecast that Atara Biotherapeutics, Inc. will post 0.2 EPS for the current year.

Analysts Set New Price Targets

ATRA has been the subject of several research analyst reports. Wall Street Zen downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings reiterated a “sell (d)” rating on shares of Atara Biotherapeutics in a research note on Friday, March 27th. Finally, Canaccord Genuity Group set a $13.00 target price on Atara Biotherapeutics and gave the stock a “buy” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Atara Biotherapeutics currently has an average rating of “Hold” and a consensus target price of $9.50.

Atara Biotherapeutics News Summary

Here are the key news stories impacting Atara Biotherapeutics this week:

• Positive Sentiment: Atara reported first-quarter 2026 financial results and operational progress, giving investors a fresh update on its T-cell immunotherapy pipeline and the status of tabelecleucel (Ebvallo) for PTLD. Article Title
• Neutral Sentiment: The company’s quarterly results showed a smaller-than-expected loss per share and revenue that beat estimates, which may help offset concern about its still-limited sales base. Article Title
• Neutral Sentiment: Several law firms issued reminders about the May 22 lead-plaintiff deadline in an existing securities class action against Atara, keeping litigation risk in focus for shareholders. Article Title
• Negative Sentiment: New and ongoing securities class-action filings alleging investor harm could pressure sentiment, especially given Atara’s small market cap and ongoing loss profile. Article Title
• Negative Sentiment: A major shareholder disclosed the sale of 313,446 shares, which can weigh on investor confidence even though insider sales do not necessarily signal trouble at the company. Article Title

Institutional Trading of Atara Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Atara Biotherapeutics by 6.6% during the 3rd quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock worth $2,915,000 after purchasing an additional 12,677 shares during the last quarter. Marshall Wace LLP lifted its holdings in Atara Biotherapeutics by 28.4% during the 4th quarter. Marshall Wace LLP now owns 148,632 shares of the biotechnology company’s stock worth $2,689,000 after purchasing an additional 32,836 shares during the last quarter. Globeflex Capital L P lifted its holdings in Atara Biotherapeutics by 399.6% during the 4th quarter. Globeflex Capital L P now owns 77,224 shares of the biotechnology company’s stock worth $1,397,000 after purchasing an additional 61,766 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in Atara Biotherapeutics by 183.5% during the 3rd quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company’s stock worth $914,000 after purchasing an additional 41,302 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Atara Biotherapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company’s stock worth $464,000 after purchasing an additional 1,457 shares during the last quarter. 70.90% of the stock is owned by institutional investors and hedge funds.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.